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Pigh-Density Lipoprotein Function
ecent Advances
enjamin J. Ansell, MD, FACC, Karol E. Watson, MD, PHD, Alan M. Fogelman, MD, FACC,
ohamad Navab, PHD, Gregg C. Fonarow, MD, FACC
os Angeles, California
Although high-density lipoproteins (HDL) possess many features that contribute to the
association between elevated HDL cholesterol and protection from atherosclerosis, these
lipoproteins may be modified in certain individuals and/or circumstances to become
proinflammatory. The ability of HDL to inhibit or paradoxically to enhance vascular
inflammation, lipid oxidation, plaque growth, and thrombosis reflects changes in specific
enzyme and protein components. The anti-inflammatory and proinflammatory functional
properties of HDL can now be assessed using cell-based and cell-free assays. Acute or chronic
systemic inflammation and the metabolic syndrome appear to render HDL proinflammatory.
In contrast, statins and experimental agents such as apolipoprotein A-1 mimetics render
HDL more anti-inflammatory. Functional characterization of HDL is a promising method
for enhanced assessment of cardiovascular risk and effectiveness of risk reduction. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.080Coll Cardiol 2005;46:1792–8) © 2005 by the American College of Cardiology Foundation
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tt is well established that the concentration of cholesterol in
igh-density lipoproteins (HDL) is an inverse predictor of
uture atherosclerotic cardiovascular disease. A growing
ody of experimental evidence suggests that augmenting the
evels and/or function of HDL and its apolipoproteins can
ave major vascular protective effects ranging from preven-
ion to stabilization and regression, independent of total or
on- high-density lipoprotein cholesterol (HDL-C) levels.
his experiment evidence and recent clinical trials have
timulated tremendous interest in the structure, function,
nd therapeutic potential of HDL.
The best-known antiatherogenic function of HDL is its
bility to promote the efflux of cholesterol from cells.
owever, HDL also has antioxidant, anti-inflammatory,
nd antithrombotic properties. It has recently been recog-
ized that HDL can both moderate as well as enhance
nflammation in atherogenesis. The anti-inflammatory
unctions of HDL include limiting lipid peroxidation,
nfluencing expression of cytokines, modulating recruit-
ent/adhesion of monocytes, and altering other aspects of
ndothelial function (1). Paradoxically, HDL particles can
lso assume proinflammatory, proatherogenic characteris-
ics, especially when an acute phase or chronic systemic
nflammatory response is present (2).
Dietary and exercise strategies can lead to modest and
ariable improvements in HDL-C concentrations and other
ascular risk factors, and may be associated with greater
ntioxidative potential of HDL (3). Both conventional
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ccepted June 7, 2005.harmacologic approaches to lipid modification with
tatins, and novel agents, such as apolipoprotein A-1 (apo-
1) mimetic peptides, can favorably impact the anti-
nflammatory/proinflammatory potential of HDL (4);
DL-C levels have limited utility in assessing an individ-
al’s risk of coronary heart disease (CHD). Functional
haracterization of HDL may allow for enhanced accuracy
n assessing cardiovascular risk as well as provide a thera-
eutic target for risk reduction. In this article, we will review
he current understanding of HDL function, its role in
therosclerosis, and the potential clinical utility of assessing
DL function.
DL structure and role in reverse cholesterol transpor-
ation. The HDL particles consist of an outer amphipathic
ayer of free cholesterol, phospholipid, and several apoli-
oproteins (apo A-I, AII, C, E, AIV, J, and D) on the
urface, with a triglyceride and cholesterol ester-rich hydro-
hobic core. Apolipoprotein A-1 is the principal protein of
DL; HDL particles also carry enzymes, such as paraoxo-
ase, platelet activating factor-acetylhydrolase, lecithin cho-
esterol acyltransferase, and cholesteryl ester transfer protein
CETP). High-density lipoprotein particles have been char-
cterized into several subtypes on the basis of ultracentrif-
gation, electrophoresis, or nuclear magnetic resonance;
hese subtypes include HDL-2 and HDL-3. The differ-
nces in particle size results mainly from the number of
polipoprotein molecules and the volume of the cholesterol
ster in the core of the particle (5).
The antiatherogenic function of HDL particles that is
ost commonly appreciated relates to its ability to promote
he efflux of cholesterol from cells, a capacity that is
enerally attributed to apoA-1. A critical function of HDL
s to mediate the efflux of cholesterol from vascular macro-
hages and other peripheral tissues, along with subsequent
ransfer of cholesteryl ester to plasma or hepatic acceptor
roteins. Efflux of cholesterol can occur by several mecha-
n
f
l
t
o
o
p
a
t
a
a
p
e
L
t
d
a
m
t
c
r
d
a
v
o
t
a
i
L
t
p
d
b
p
i
H
i
p
m
H
m
p
W
v
p
I
L
h
e
E
p
o
i
u
h
p
n
d
m
e
t
c
H
c
e
d
a
(
t
i
a
m
t
e
H
o
a
c
m
H
t
m
g
d
l
a
s
b
t
H
m
k
l
1793JACC Vol. 46, No. 10, 2005 Ansell et al.
November 15, 2005:1792–8 Functional Properties of HDLisms, including: 1) passive diffusion of free cholesterol
rom the macrophage, with subsequent esterification by
ecithin:cholesterol acyltransferase associated with HDL; 2)
ransport of cholesterol to HDL via scavenger receptor B1
n the vessel wall surface; and 3) most significantly, binding
f lipid-poor apoA-1 to the ATP-binding cassette trans-
orter A1 (ABCA1) transporter in the vessel wall, where it
ccepts free cholesterol, forming pre-beta HDL that ma-
ures through esterification to alpha migrating HDL (6). In
ddition to its role in reverse-cholesterol transport, HDL
lso has antioxidant, anti-inflammatory, and antithrombotic
roperties that play an important role in the antiatherogenic
ffects of HDL.
ipid oxidation in atherosclerosis. Oxidation is central to
he initiation and propagation of atherosclerosis (4). Oxi-
ation of phospholipids within LDL by oxidized lipids such
s fatty acid hydroperoxides leads to the production of
inimally modified LDL that initiates a sequence of events
hat lead to the initial fatty streak (7). Lipid hydroperoxides
an also decrease nitric oxide production and the vasomotor
esponse of the arterial wall in vitro (8). Oxidized low-
ensity lipoprotein (ox-LDL) is also associated with LDL
ggregation in vivo and coronary artery cell toxicity in
itro (9). Jessup (10) suggested that a “self-reinforcing cycle”
f unencumbered lipid peroxidation and nitric oxide deple-
ion can contribute to the accelerated development of
therosclerosis.
Lipid oxidation contributes to vascular inflammation and
s more likely when systemic inflammation is present.
eukocytes from patients with either systemic lupus ery-
hematosus or rheumatoid arthritis show enhanced lipid
eroxidation (11,12) and LDL oxidation (13). These hy-
roperoxides (products of the 5-lipoxygenase pathway) are
actericidal and cytotoxic (12). The LDL oxidation and
lasma lipid peroxide are also increased during systemic
nfection (14) and the metabolic syndrome (15).
DL as an antioxidant. High-density lipoprotein plays an
mportant role as an antioxidant by both inhibiting phos-
holipid oxidation within and reducing the activity of
inimally modified LDL (16). Several components of
DL contribute to this antioxidant effect, including its
Abbreviations and Acronyms
ABCA1  adenosine triphosphate-binding cassette
transporter A1
apoA-1  apolipoprotein A-1
CETP  cholesteryl ester transfer protein
CFA  cell-free assay
CHD  coronary heart disease
HDL  high-density lipoprotein
HDL-C  high-density lipoprotein cholesterol
LDL  low-density lipoprotein
MCA  monocyte chemotaxis assay
MCP  monocyte chemotaxis protein
ox-LDL  oxidized low-density lipoproteinajor apoA-1 along with at least four enzymes, including aaraoxanase 1 and lecithin:cholesterol acyltransferase (17).
atson et al. (16) demonstrated that paraoxanase 1 pre-
ents the formation of lipid hydroperoxides and oxidized
hospholipids and hydrolyzes them once they are formed.
n vitro, apoA-1 also reduces lipid hydroperoxides within
DL independent of paraoxanase (18). Graham et al. (19)
ave shown that phospholipids in the HDL-3 fraction are
specially capable of retarding LDL oxidation.
vidence that HDL can be a pro-oxidant. In many
atients with atherosclerosis, it appears that HDL is not
nly ineffective as an antioxidant, but it paradoxically
ncreases lipid peroxide formation. In addition to being
nable to retard LDL oxidation, HDL from patients with a
istory of CHD enhances the oxidation of LDL and
hospholipids in LDL (20). Oxidation of HDL per se does
ot necessarily generate ineffective HDL, however. Mac-
onald et al. (21) reported that tyrosyl radical oxidation of
ouse HDL enhances its ability to promote cholesterol
fflux in vitro and inhibits aortic lesion development better
han control HDL or saline (p  0.001).
While tyrosyl radical oxidation of HDL can augment
holesterol efflux, oxidation and subsequent nitration of
DL have the opposite effect. An antioxidant under normal
onditions, endothelial nitric oxide can be altered by my-
loperoxidase from phagocytic cells to create nitric-oxide-
erived oxygen species that can promote oxidative nitration
nd halogenation products within a developing atheroma
22,23). Zheng et al. (22) identified apoA-1 as a specific
arget of myeloperoxidase that, when oxidized and nitrated,
mpaired ABCA1-dependent cholesterol efflux.
Nitrotyrosine and/or chlorotyrosine modification of
poA-1 is inversely correlated with HDL’s ability to pro-
ote efflux (22). Bergt et al. (24) showed that HDL from
he blood of human subjects with coronary disease contains
levated levels of 3-chlorotyrosine compared to circulating
DL from healthy subjects. Furthermore, exposing HDL
r apoA-1 to the myeloperoxidase product hydrochlorous
cid almost entirely prevented ABCA1-dependent reverse
holesterol transport. Figure 1 summarizes the role of
yeloperoxidase in catalyzing oxidative modification of
DL, rendering it unable to effect ABCA1-mediated
ransport.
Analogous to its adverse effects on HDL function,
yeloperoxidase may also inhibit endothelial cell function,
iven the strong inverse relationship between flow-mediated
ilation of the brachial artery and serum myeloperoxidase
evel (25). Based on its potential linkage between oxidation
nd vascular inflammation, Nicholls and Hazen (23) have
uggested that myeloperoxidase itself may be an important
iomarker of atherosclerotic risk as well as a target for
herapeutic intervention.
DL retarding monocyte recruitment, expression of
onocyte chemotaxis protein (MCP)-1 and other cyto-
ines. In response to the production of oxidized phospho-
ipids within the subendothelial space of a developing
therosclerotic plaque, MCP-1 is produced by the vascular
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Functional Properties of HDL November 15, 2005:1792–8ndothelial cells (26). There is therefore linkage between
he production of oxidized lipids and cellular inflammation,
nd anti-inflammatory HDL appears to moderate both of
hese processes.
Another important anti-inflammatory role of HDL is to
imit the expression of cytokines such as tumor necrosis
actor-alpha, and interleukin-1 that mediate up-regulation
f leukocyte endothelial adhesion molecules. Cockerill and
arter (27) have shown that human endothelial cells, when
retreated with HDL, show markedly reduced expression of
eukocyte adhesion molecules when stimulated by these
nflammatory cytokines.
aradoxical enhancement of MCP-1 expression by
DL. Conversely, HDL can also act to amplify vascular
nflammation. Ansell et al. (20) demonstrated that the
DL from 77% of statin-naive patients with CHD or
HD risk equivalents enhanced LDL-induced recruitment
f monocytes in an experimental co-culture of endothelial
nd smooth muscle cells. This contrasted with none of the
ge-/gender-matched controls from whom proinflamma-
ory HDL was identified using this monocyte chemotaxis
ssay (MCA) (20). The “inflammatory index” comparing
he effects of LDL with and without HDL (defined as 1.0)
as 1.38  0.91 in patients versus 0.38  0.14 in controls
p 0.000015). Thus, the inflammatory/anti-inflammatory
roperties of HDL distinguished CHD patients from con-
rols better than did HDL-C concentration, which was
ore comparable between the control and CHD groups
20).
Similar results were seen using a cell-free assay (CFA)
omparing the ability of HDL from CHD patients and
ontrols to retard phospholipid oxidation (20). In this
nalysis, the HDL from 96% of CHD patients was proin-
igure 1. Model of bidirectional conversion of high-density lipoprotein
yeloperoxidase in catalyzing oxidative modification of HDL, render
1-mediated cholesterol transport, modified from Fogelman et al. (2). In
evels decrease, while proinflammatory factors such as lipid oxidation prodammatory (paradoxically enhanced phospholipid oxidation aompared with the production of oxidized phospholipid in
he absence of HDL), while none of the controls exhibited
roinflammatory HDL by the CFA (20). Using the CFA,
he inflammatory index of the patients was 1.19  0.19
ompared to that for the controls at 0.53  0.15 (20).
elationship of anti-inflammatory/proinflammatory
roperties of HDL to reverse cholesterol transport. The
bility of HDL to facilitate cellular cholesterol efflux may be
irectly related to its anti-inflammatory/inflammatory prop-
rties. In the Ansell et al. (28) study, the ability of a subject’s
DL to inhibit monocyte chemotaxis was highly correlated
ith its capacity to promote cholesterol efflux. Impaired
everse cholesterol transport by HDL leads to increased
evels of atherogenic lipoproteins and increased levels of
xidized lipids, which are themselves proinflammatory (29).
odifiers of HDL anti-inflammatory/inflammatory ac-
ivity. The potential for HDL to inhibit lipid oxidation
nd/or monocyte recruitment appears to be modifiable by
he acute phase response, medications, and HDL mimetics.
cute phase response HDL. The acute phase response
as both quantitative and qualitative effects on HDL and its
onstituents (30). Rohrer et al. (31) reported that inflam-
ation reduces HDL-C by increasing the activities of
ndothelial lipase and soluble phospholipase A2 and by
eplacing apoA-1 in HDL with serum amyloid A. As
xamples, sepsis or influenza infection can decrease the
oncentration of HDL-C in humans by as much as 50%
32).
Inflammation also causes significant changes in the pro-
ein and lipid composition of HDL (Fig. 2). In a mouse
odel, Van Lenten et al. (33) demonstrated that acute
nfluenza infection impaired HDL’s anti-inflammatory ca-
abilities by reducing levels of paraoxonase and platelet-
L) from anti-inflammatory (a) to proinflammatory (b), and the role of
unable to effect adenosine triphosphate-binding cassette transporter
iation with these changes, apolipoprotein A-1 (apoA-1) and paraoxonase
increase.(HD
ing itctivating factor acetylhydrolase, while increasing cerulo-
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November 15, 2005:1792–8 Functional Properties of HDLlasmin, and apolipoprotein J within HDL. In humans
ndergoing elective laparoscopic cholecystectomy, levels of
araoxanase and lecithin:cholesterol acyltransferase fell 24%
nd 44%, respectively, to a nadir three to six days postop-
ratively (34). These alterations in antioxidative capacity
llow for increased production of ox-LDL and minimally
odified LDL that contributes to the production of inflam-
atory cytokines by smooth muscle and endothelial cells.
harmacologic modulation: statin effect. In contrast to
he effects of systemic inflammation, statin therapy appears
o lessen the proinflammatory potential of HDL. While
tatin treatment is associated with a relatively minimal effect
n HDL-C concentration, changes in HDL’s anti-
nflammatory/inflammatory potential may be greater.
In the Ansell et al. (20) study in the preceding text, after
ix weeks of treatment with simvastatin 40 mg daily, HDL
ecame anti-inflammatory in 46% (vs. 23% at baseline) of
HD/risk equivalent patients’ cases by the MCA and 58%
vs. 4% at baseline) by the CFA. This suggests that
onventional statin treatment in CHD patients is associated
ith enhancement of HDL’s ability to limit monocyte
hemotaxis and phospholipid oxidation. However, the in-
ammatory index of HDL from these statin-treated pa-
ients (1.08  0.71) still did not reach the very anti-
nflammatory level (0.38  0.14) seen in the controls, as
hown in Figure 3 (20).
harmacologic modulation: HDL and its analogues.
uccess of traditional pharmacotherapy directed toward
DL has largely been measured by increases in HDL-C
igure 2. Enzymatic and protein changes within high-density lipoprotein (
( J), and secretory nonpancreatic phospholipase A2 (sPLA2) are presen
omponents apolipoprotein A-I (A-I), paraoxonase 1 (PON1), platelet
CETP), lecithin:cholesterol acyltransferase (LCAT), and phospholipid tra
ipoprotein phospholipid content also falls, along with a reduction in choles
-II  apolipoprotein A-II. From Rohrer et al. (31).oncentration, which can be difficult to achieve in practice. ht is assumed that an increase in HDL-C will lead to
eduction in CHD events, such as the robust treatment
ffects that were seen in the HDL Atherosclerosis Treat-
ent study and the Veterans Administration HDL Inter-
ention trial (35,36). Although post-hoc analysis of the
atter trial’s results suggested that the 6% increase in
DL-C was the only predictor of response to gemfibrozil,
his analysis: 1) showed that only 23% of the reduction in
HD could be attributed to the rise in HDL-C; and 2) did
ot consider other potentially beneficial effects, including
ualitative changes in LDL and/or HDL (37).
Emerging strategies to raise HDL-C to a greater extent
han currently possible, such as the 40% to 61% shown with
he CETP inhibitor torcetrapib in combination with ator-
astatin, are promising but still require demonstration of
linical benefits (38). The relationship between CETP and
therosclerosis is complex, and both proatherogenic and
ntiatherogenic effects have been suggested; CETP may be
therogenic because of its ability to transfer cholesterol ester
rom HDL to LDL/very low-density lipoprotein (VLDL),
hus lowering plasma levels of HDL while increasing the
evels of LDL/VLDL. Conversely, CETP may also be
ntiatherogenic by facilitating the production of lipid-poor
re-HDL particles, which are efficient stimulators of reverse
holesterol transport. Both experimental and human epide-
iological studies have provided conflicting data (39).
Infusions of HDL and its analogues have shown anti-
nflammatory effects and regression of atherosclerosis. An-
elin et al. (40) reported that intravenous treatment of
) during an acute phase reaction. Serum amyloid A (SAA), apolipoprotein
igher serum concentrations and incorporate into HDL, while the HDL
ting factor acyl hydrolase (PAF-AH), cholesteryl ester transfer protein
protein (PLTP) all decrease in concentration within HDL. High-density
esters and an increase in triglycerides, free fatty acids, and free cholesterol.HDL
t at h
activa
nsferumans with pro-apoA-1 liposomal complexes resulted in
i
t
c
m
l
(
e
e
e
v
c
h
s
M
i
a
a
c
s
o
r
i
i
a
z
o
c
N
D
7
c
p
a
P
d
c
d
D
l
v
i
c
H
r
c
e
(
P
M
i
C
c
c
s
m
a
H
i
t
i
o
f
t
l
i
H
m
l
e
p
p
F

m
h
e
(
H
a
1796 Ansell et al. JACC Vol. 46, No. 10, 2005
Functional Properties of HDL November 15, 2005:1792–8ncreased fecal sterol content without an increase in choles-
erol synthesis, suggesting a significant increase in reverse
holesterol transport. Reports of similar infusions in hu-
ans have shown a significant increase in pre-beta HDL
evels, evidence of enhanced reverse cholesterol transport
41), and a significant reduction in the inflammatory prop-
rties of LDL (42). Badimon et al. (43) published the first
vidence that infusion of HDL allowed for regression of
xisting atherosclerosis in a rabbit model.
As apoA-1 contains 243 amino acids and requires intra-
enous infusion, it has limited clinical utility. Human
arriers of a naturally occurring variant, apoA-1 Milano,
ave surprising longevity and apparently little atherosclero-
is despite low HDL-C levels (44). Recombinant apoA-1
ilano/phospholipid complexes administered in five weekly
ntravenous infusions to a cohort of 47 human patients with
cute coronary syndromes resulted in a 4.2% reduction in
theroma volume from baseline, as determined by intravas-
ular ultrasound (p  0.001); placebo treatment had no
igure 3. (A) High-density lipoprotein (HDL) inflammatory index (mean
SD), as determined by comparing low-density-lipoprotein-induced
onocyte migration in an artery wall cell co-culture assay with HDL from
ealthy controls, HDL from patients with coronary heart disease/risk
quivalents before/after simvastatin 40 mg/day for six weeks, and no HDL
defined as an inflammatory index of 1.0). From Navab et al. (4). (B)
igh-density lipoprotein inflammatory index from the same subjects, using
cell-free assay.ignificant effect (45). The long-term effects and practicality tf such a strategy remain to be demonstrated, but the rapid
egression in human atherosclerotic plaque seen in this trial
s unprecedented.
The search for an orally active apo-A1 mimetic that
mproves HDL function yielded D-4F, an 18 D-amino acid
mphipathic peptide able to withstand gastrointestinal en-
ymes that digest L-amino acids. The order and orientation
f these amino acids within this compound are exquisitely
ritical to its effectiveness in retarding atherosclerosis (46).
avab et al. (47) reported that twice-daily oral ingestion of
-4F in LDL receptor-null mice diminished lesion size by
9% without significant change in plasma cholesterol con-
entrations. Oral treatment of apo-E–null mice with the
eptide also resulted in a marked increase in pre-beta HDL
nd increased cholesterol efflux from macrophages (48).
lasma from the mice 20 min after receiving oral D-4F
emonstrated cholesterol-containing particles similar to mi-
elles with high apoA-1 content, paraoxanase activity, and
ecreased lipid hydroperoxides (48).
Van Lenten et al. (49) also recently demonstrated that
-4F was able to retard the secretion of oxidized phospho-
ipids by pneumocytes in response to influenza infection in
itro, demonstrating that apoA-1 mimetics can have anti-
nflammatory properties outside the vasculature. This is
onsistent with the suggestion by Navab et al. (50) that
DL is part of a system of nonspecific innate immunity. In
odents, infusions of HDL have limited the clinical, bio-
hemical, and histological signs of inflammation from mes-
nteric ischemia/reperfusion (51,52) and endotoxic shock
52).
otential clinical applications of HDL functional testing.
easurement of HDL anti-inflammatory/inflammatory activ-
ty has potential for both defining patients at increased risk of
HD as well as monitoring the effectiveness of therapies
apable of modifying these properties. Observing qualitative
hanges in HDL could assess an individual’s biological re-
ponse to new therapies such as apoA-1 mimetics, which have
inimal/no effect on plasma lipoprotein concentrations. In
ddition, it will be important to characterize the function of
DL in clinical trials of torcetrapib, while awaiting studies of
ts effects on atherosclerosis. The functionality of HDL after
orcetrapib treatment has not yet been reported but could have
mportant clinical implications, as the antiatherogenic potential
f this therapeutic strategy is controversial (53).
Characterizing HDL anti-inflammatory/inflammatory
unction could also allow for identification of the presump-
ive minority among those patients with elevated HDL-C
evels who are at heightened risk for CHD based on an
nflammatory HDL phenotype. Most patients with elevated
DL-C concentrations are not candidates for lipid-
odifying therapy according to current treatment guide-
ines, but some nonetheless remain at risk for coronary
vents (54). Determining HDL function may also identify
atients with normal or low HDL levels that are at
articularly high risk for cardiovascular events. In addition
o identifying a population with dysfunctional HDL that
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November 15, 2005:1792–8 Functional Properties of HDLight possibly benefit from treatments such as apoA-1
imetics, recognition of proinflammatory HDL might also
ustify traditional LDL-lowering approaches such as statin
herapy in this group, given evidence that statin therapy also
oderates HDL dysfunction (2). In individuals with the
etabolic syndrome, in whom a constellation of subtle
etabolic markers confers increased CHD risk, evaluation
f HDL anti-inflammatory/inflammatory activity might
rovide an integrated assessment of the severity of their
ncreased risk. Such testing might also allow assessment of
hether treatment has successfully improved HDL function
n an individual patient. It will also be important to
ncorporate testing of HDL function in clinical trials and
tudies assessing the risk of future cardiovascular events.
onclusions. High-density lipoprotein has a variety of
unctional effects including both proinflammatory and anti-
nflammatory properties. The serum HDL-C level does not
ssess HDL’s functional properties. Even within a normal
ndividual, HDL may become transiently pro-oxidant in the
resence of systemic infection. Determination of HDL
nti-inflammatory/proinflammatory function will likely
ield important additional information beyond that avail-
ble from simply knowing the quantitative level of HDL-C
n an individual. This additional information will likely
mprove predictive accuracy for CHD and may also provide
ew strategies for the prevention and treatment of
therosclerosis.
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